EVLO (Evelo Biosciences) Net Income (Continuing Operations): $-82.35 Mil (TTM As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Evelo Biosciences Net Income (Continuing Operations)?

Evelo Biosciences EVLO -99.00% Net Income (Continuing Operations) is $-82.35 Mil as of Sep. 2023.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Evelo Biosciences's Net Income (Continuing Operations) for the three months ended in Sep. 2023 was $-12.36 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 was $-82.35 Mil.

Evelo Biosciences  (OTCPK:EVLO) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Evelo Biosciences Net Income (Continuing Operations) Related Terms

Evelo Biosciences Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences Net Income (Continuing Operations) Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income (Continuing Operations)
Get a 7-Day Free Trial -56.95 -85.47 -93.67 -122.18 -114.53

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.56 -23.54 -25.34 -21.10 -12.36

Evelo Biosciences Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-82.35 Mil mean?
Evelo Biosciences (EVLO) has a Net Income (Continuing Operations) of $-82.35 Mil as of Sep. 2023. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Evelo Biosciences and its competitors.
Is Evelo Biosciences' Net Income (Continuing Operations) too high?
Evelo Biosciences' current Net Income (Continuing Operations) is $-82.35 Mil.
How does Evelo Biosciences' Net Income (Continuing Operations) compare to IMNN and EDSA?
Evelo Biosciences' Net Income (Continuing Operations) of $-82.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Evelo Biosciences and its competitors. Evelo Biosciences's current Net Income (Continuing Operations) is $-82.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current Net Income (Continuing Operations) of $-82.35 Mil. The current Net Income (Continuing Operations) is $-82.35 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current Net Income (Continuing Operations) is $-82.35 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.